Logo image of NRX.CA

NUREXONE BIOLOGIC INC (NRX.CA) Stock Fundamental Analysis

Canada - TSX-V:NRX - CA67059R1091 - Common Stock

1.01 CAD
-0.04 (-3.81%)
Last: 9/25/2025, 7:00:00 PM
Fundamental Rating

2

NRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 24 industry peers in the Biotechnology industry. While NRX seems to be doing ok healthwise, there are quite some concerns on its profitability. NRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NRX had negative earnings in the past year.
In the past year NRX has reported a negative cash flow from operations.
NRX had negative earnings in each of the past 5 years.
In the past 5 years NRX always reported negative operating cash flow.
NRX.CA Yearly Net Income VS EBIT VS OCF VS FCFNRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

NRX has a worse Return On Assets (-220.67%) than 62.50% of its industry peers.
NRX's Return On Equity of -412.53% is in line compared to the rest of the industry. NRX outperforms 58.33% of its industry peers.
Industry RankSector Rank
ROA -220.67%
ROE -412.53%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRX.CA Yearly ROA, ROE, ROICNRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRX.CA Yearly Profit, Operating, Gross MarginsNRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

There is no outstanding debt for NRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NRX.CA Yearly Shares OutstandingNRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
NRX.CA Yearly Total Debt VS Total AssetsNRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M

2.2 Solvency

An Altman-Z score of 9.48 indicates that NRX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.48, NRX belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
A Debt/Equity ratio of 0.06 indicates that NRX is not too dependend on debt financing.
NRX has a better Debt to Equity ratio (0.06) than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 9.48
ROIC/WACCN/A
WACCN/A
NRX.CA Yearly LT Debt VS Equity VS FCFNRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M

2.3 Liquidity

A Current Ratio of 1.94 indicates that NRX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.94, NRX is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
NRX has a Quick Ratio of 1.94. This is a normal value and indicates that NRX is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.94, NRX is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.94
NRX.CA Yearly Current Assets VS Current LiabilitesNRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for NRX have decreased strongly by -10.90% in the last year.
EPS 1Y (TTM)-10.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.80% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2Y11.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRX.CA Yearly EPS VS EstimatesNRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -0.02 -0.04 -0.06 -0.08

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRX. In the last year negative earnings were reported.
Also next year NRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRX.CA Price Earnings VS Forward Price EarningsNRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRX.CA Per share dataNRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.8%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUREXONE BIOLOGIC INC

TSX-V:NRX (9/25/2025, 7:00:00 PM)

1.01

-0.04 (-3.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-27 2025-08-27/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.89%
Ins Owner ChangeN/A
Market Cap82.29M
Analysts84.44
Price Target3.12 (208.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.08%
Min EPS beat(2)-16.5%
Max EPS beat(2)-11.65%
EPS beat(4)1
Avg EPS beat(4)-2.35%
Min EPS beat(4)-16.5%
Max EPS beat(4)35.28%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 38.66
P/tB 38.66
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS0.03
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -220.67%
ROE -412.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 268.31%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.94
Altman-Z 9.48
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)664.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y0%
EPS Next 2Y11.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-230.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-217.65%
OCF growth 3YN/A
OCF growth 5YN/A